Nippon Shinyaku Co., Ltd. (TYO:4516)
3,339.00
+46.00 (1.40%)
Sep 16, 2025, 3:30 PM JST
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 39.55B JPY in the quarter ending June 30, 2025, with 1.06% growth. This brings the company's revenue in the last twelve months to 160.65B, up 6.83% year-over-year. In the fiscal year ending March 31, 2025, Nippon Shinyaku had annual revenue of 160.23B with 8.08% growth.
Revenue (ttm)
160.65B
Revenue Growth
+6.83%
P/S Ratio
1.38
Revenue / Employee
71.62M
Employees
2,243
Market Cap
221.88B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.21B |
HOYA Corporation | 876.09B |
Takeda Pharmaceutical Company | 4,480.25B |
Daiichi Sankyo Company | 1,924.68B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |
Nippon Shinyaku News
- 8 months ago - Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
- 8 months ago - REGENXBIO partners with Nippon Shinyaku for MPS therapies - Seeking Alpha
- 8 months ago - Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
- 1 year ago - Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha
- 1 year ago - Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - Seeking Alpha
- 1 year ago - EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga